2 Small-Cap Stocks to Research Further and 1 Facing Challenges
Fortrea Holdings Inc FTRE
$19.89
▼ -0.65%
($-0.13)
Open
$19.90
Prev Close
$20.02
Day Range
$19.35 – $20.29
52W Range
$8.31 – $21.39
Market Cap
$1.89B
Beta
1.95
EPS (TTM)
$-0.91
📋 Company Profile
| Industry | Life Sciences Tools & Services |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-06-16 |
| Shares Out. | 95,100,000 |
| Website | fortrea.com/ ↗ |
| Phone | 13026365400 |
| Employees | 14,000 |
| Revenue | $678.2M |
| Gross Profit | $139.2M |
| Net Income | -$13.2M |
| Free Cash Flow | $196.0M |
| Total Assets | $2.71B |
| Total Liabilities | $2.19B |
| Equity | $524.2M |
About Fortrea Holdings Inc
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
Fortrea Holdings Inc is a publicly traded company under the ticker symbol FTRE on the NASDAQ NMS - GLOBAL MARKET, operating in the Life Sciences Tools & Services industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-09-01)